Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

73.68
-0.5900-0.79%
Post-market: 74.560.8800+1.19%16:39 EDT
Volume:1.12M
Turnover:82.93M
Market Cap:8.14B
PE:43.80
High:74.35
Open:74.12
Low:73.64
Close:74.27
Loading ...

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

GlobeNewswire
·
1 hour ago

MannKind, Blackstone Agree to $500 Million Credit Facility

MT Newswires Live
·
Yesterday

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

GlobeNewswire
·
Yesterday

Agree Realty Corporation Releases Transcript for Second Quarter 2025 Earnings Call

Reuters
·
Yesterday

Analysts Offer Insights on Real Estate Companies: Arbor Realty (ABR), Agree Realty (ADC) and SITE Centers (SITC)

TIPRANKS
·
04 Aug

RBC Capital Sticks to Their Buy Rating for Agree Realty (ADC)

TIPRANKS
·
04 Aug

Better Dividend Stock: Sun Communities vs. Agree Realty

Motley Fool
·
04 Aug

Evercore ISI Sticks to Their Buy Rating for Agree Realty (ADC)

TIPRANKS
·
04 Aug

Agree Realty’s Strong Financial Performance and Strategic Positioning Reinforce Buy Rating

TIPRANKS
·
01 Aug

Agree Realty Corp reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
01 Aug

Earnings Flash (ADC) Agree Realty Q2 Adjusted FFO $1.06 Vs. FactSet Est. $1.06

MT Newswires Live
·
01 Aug

Agree Realty reports Q2 AFFO $1.06, consensus $1.06

TIPRANKS
·
01 Aug

Agree Realty raises FY25 AFFO view to $4.29-$4.32 from $4.27-$4.30

TIPRANKS
·
01 Aug

Agree Realty Q2 FFO $1.06 Beats $1.05 Estimate, Sales $175.527M Beat $170.935M Estimate

Benzinga
·
01 Aug

Agree Realty Corp: Raises 2025 Investment Guidance to $1.4 Bln to $1.6 Bln

THOMSON REUTERS
·
01 Aug

Agree Realty Corp: Increases 2025 Affo per Share Guidance to $4.29 to $4.32

THOMSON REUTERS
·
01 Aug

Agree Realty Q2 Core Ffo USD 115.9 Million

THOMSON REUTERS
·
01 Aug

Agree Realty Outlook FY Adjusted Ffo per Share USD 4.29-4.32

THOMSON REUTERS
·
01 Aug

Agree Realty Corp FY2025 Ffo Shr View $4.25 -- Lseg Ibes Data

THOMSON REUTERS
·
01 Aug

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress

GlobeNewswire
·
30 Jul